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1. Introduction 
Alcoholism is a complex relapsing disorder of heterogeneous etiology, affecting people 
internationally. Alcohol dependence is a cumulative response of inability to stop drinking, 
craving and developing the symptoms of physical dependence and tolerance. In past two 
decades, mounting evidence has suggested that alcoholism or alcohol addiction is a host of 
major psychological, social, financial and health problems (Poznyak et al., 2005). According 
to World Health Organization, alcoholism is responsible for 4% of global disease burden 
and is the third major preventable risk factor for premature death and disability in 
developed nations (World Health Organization, 2002). Although, the exclusive biological 
mechanisms underlying the development of alcoholism are still uncertain, the major risk 
factors contributing towards the development of alcoholism are age (adolescents are at 
higher risk of developing alcoholism), gender (men are more prone to develop alcoholism as 
compared to women due to depression), personality (experience seeking), and psychiatric or 
behavioral disorders. The prevalence, age of onset, clinical symptoms and outcome of 
alcoholism differs from individual to individual and varies according to ethnicity (Kenneth 
et al., 2011). In addition to this, lower social status and low education have also been found 
to be associated with alcoholism in cross sectional and longitudinal studies (Fukuda et al., 
2005; Poznyak et al., 2005; Subramanian et al., 2005; Wray et al., 2005).  
According to World Health Organization report on global alcohol status, it has been found 
that approximately 2 billion people consume alcoholic beverages and there are about 76.3 
million people with diagnosable alcohol disorder (World Health Organization, 2004). In 
India the prevalence of alcoholism has been found to be 21.4% as recoded by 
epidemiological surveys (Benegal, 2005).The deleterious effects of alcohol on central nervous 
system can be observed in the form of changes in mood and personality, anxiety and 
depression. Although, it affects all the organs in the body, brain neurotransmitters are the 
main target sites of alcohol (Wertheimer et al., 2003). The specific physiological effects of 
alcohol depend on dose, concentration in blood, absorption, distribution, metabolism, 
excretory conditions, prior drinking experience, concurrent use of other drugs, and 
                                                 





comorbid conditions. The body adapts metabolically and neurally to repeated exposure of 
alcohol so as to develop tolerance (Zaleski et al., 2004).  
Recent advances in the field of neurobiology have improved our understanding about 
associated risk factors and neurochemical mechanisms responsible for the development of 
alcoholism. Evidences suggest that there is large inter-individual variation in terms of 
development of alcohol dependence and treatment of alcoholism. People consume alcohol 
and respond to its effects in a number of ways e.g. some develop no side effects even in 
moderate to higher levels and some may develop problems even when consumed in smaller 
doses. This variation is the result of individual’s genetic makeup directly influencing the 
metabolism of alcohol (Strat et al., 2008).  
Genetic factors have been found to play a critical role in the etiology of alcoholism (Heath et 
al., 2001; Sloan et al., 2008; Kenneth et al., 2011). Researchers have suggested that 50-60% of 
alcohol dependence is determined by genetics (Goldman and Bergen 1998; McGue et al., 1999). 
Based on results of adoption, twin, and family studies it is now clear that the vulnerability to 
alcoholism is determined by genetic factors as well as by environmental factors (Moussas et al., 
2009). However, it is difficult to determine the individual determinant of alcoholism 
(Flensborg-Madsen et al., 2007). The candidate gene approach has revealed a number of 
biomarkers, which are responsible for alcoholism. Certain variants of alcohol dehydrogenase 
and aldehyde dehydrogenase genes (genes encoding for alcohol metabolizing enzymes) have 
been found to alter the metabolism of alcohol in a dramatic way (Nurnberger et al., 2004). In 
addition to this, polymorphisms in neurotransmitter genes (target receptor genes) such as 
gamma amino butyric acid and opioid receptor genes have also been reported to be associated 
with marked risk of alcohol dependence (Strat et al., 2008). Current treatment approaches to 
alcoholism are moderately effective with perhaps as many as half of the patients receiving 
treatment due to abstinent or significantly reducing episodes of binge drinking (Group, 1997). 
Pharmacotherapy and behavioral therapy including psychosocial support are two main types 
of treatment in alcoholism. The pharmacological agents approved by FDA prescribed in the 
treatment of alcoholism are disulfiran (antabuse), naltrexone (revia), acamprosate (campral) 
and Vivitrol (Krishnan-Sarin & O’Malley et al., 2008). 
The major drawback of ineffectiveness of pharmacotherapy of alcoholism is inter-individual 
variation in response to medication (Radel and Goldman, 2001). There are individuals, 
showing lesser/no therapeutic efficacy of a drug prescribed, known as non-responders. 
Another group of individuals showing high therapeutic efficacy towards the same drug are 
known as responders (McLeod et al., 2000).  
Recent advances in the area of molecular biology have increased our knowledge of 
understanding the influence of genetic variants on pharmacokinetic and pharmacodynamic 
profile of alcohol and neurobiology of alcoholism (Ray et al., 2010a). The unavoidable 
alcohol withdrawl symptoms, depression, unpredicted death, medical complications, 
socioeconomic repercussions of alcoholism suggest that the treatment strategies should be 
improved with new and targeted approach of pharmacogenetics.  
Pharmacogenetics is a measure of predicting individual’s genetic profile responsible for 
variable drug responses. The genetic analysis along with consideration of other factors of 
alcoholic patients can lead to the identification of clinical subtypes of patients with specific 
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treatments. This will improve the treatment of alcoholism. Alcohol pharmacogenetics has 
great potential in improving treatment strategies for alcoholism (Radel and Goldman, 2001; 
Quickfall and el-Guebaly, 2006). The treatment strategy of combining clinician’s views based 
on genotypic information would individualize and optimize the treatment for alcoholism 
with best possible outcome of individual’s good health free of alcohol dependence. 
Pharmacogenetics is expected to add new dimensions and would tailor the therapeutic 
treatment of alcoholism. 
The chapter provides an overview of the molecular, pharmacological and neurological 
aspects of alcoholism with main emphasis on pharmacogenetics of alcoholism treatment.  
2. Metabolism of alcohol 
Alcohol is generally taken orally, absorbed unchanged through the whole length of 
digestive tract. Almost 20% absorption takes place rapidly through stomach and 80% 
through small gut (Caballeria, 2003). The rate of absorption depends on volume, 
concentration, nature of alcoholic drink, presence and absence of food in stomach, 
permeability of gastric and intestinal tissues and genetic variation. After absorption into the 
blood-stream, alcohol is distributed quickly throughout the total body fluid (Pawan, 1972). 
The distribution of alcohol is accelerated by vascularization and blood flow e.g. organs rich 
in blood supply such as brain and lungs achieve the higher initial concentrations of alcohol.  
Liver is the main site of alcohol metabolism. In hepatocytes three systems are involved in 
alcohol metabolism located in three different cellular compartments. These are alcohol 
dehydrogenase (ADH) located in cytosol, microsomal ethanol oxidizing system (MEOS) 
situated in endoplasmic reticulum and catalase in peroxisomes (Caballeria, 2003). These are 
involved in conversion of alcohol to acetaldehyde (Figure 1). 
The metabolic pathway involves conversion of alcohol (ethanol) to acetaldehyde via 
oxidation catalyzed by ADH in cytoplasm of hepatocytes, a rate limiting step. The second 
reaction is catalyzed by aldehyde dehydrogenases (ALDH), acetaldehyde is converted to 
acetic acid and finally to carbon dioxide and water through citric acid cycle into circulation. 
Acetaldehyde plays central role in the toxicity produced by alcohol consumption as in liver 
it reaches to saturation point and escapes into blood circulation. Further it impairs 
mitochondrial functions and reactions leading to damage of hepatocytes. The rate of 
metabolism of alcohol differs from person to person because it is influenced by genetic 
variants of metabolizing enzymes mentioned above (Quertemont, 2004).  
2.1 Alcohol dehydrogenase system 
Alcohol dehydrogenase (ADH) occurs in multiple forms and is encoded by 7 different 
genes. These are ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6 and ADH7. These genes 
are aligned along a small region of chromosome 4. ADH enzymes encoded by ADH gene 
function as dimers i.e. the active forms are composed of two subunits. On the basis of their 
similar amino acid sequences and kinetic properties, these seven ADH types have been 
divided into five classes. The class I genes ADH1A, ADH1B and ADH1C are closely related. 
These encode for ǂ, ǃ and Ǆ subunits respectively, which form homodimers or heterodimers 





2006). Further, ADH1A, ADH1B and ADH1C are mainly present in liver and linings of 
stomach. ADH4 encodes π-ADH which has been reported to contribute significantly to 
ethanol oxidation at higher concentration. The ADH5 gene encodes for χ-ADH, a 
ubiquitously expressed formaldehyde dehydrogenase, which has low affinity for ethanol. 
ADH6 mRNA is found in fetal and adult liver. Since the enzyme has not been isolated from 
tissues so far, therefore little is known about it. ADH7 encodes for σ-ADH, which oxidizes 
both ethanol and retinol (Edenberg, 2007). 
2.2 Aldehyde dehydrogenase  
These enzymes rapidly convert acetaldehyde to acetate using cofactor NAD+ via oxidation. 
ALDH is divided into nine major categories. Some of these are significantly involved in 
acetaldehyde metabolism, and others metabolize a variety of substrates. Two main ALDH 
enzymes reported to be involved in metabolization of acetaldehyde during the oxidation of 
ethanol are ALDH1 and ALDH2. ALDH1 encoded by ALDH1A1 gene is found in fluid 
filling cells (the cytosol) while ALDH2 is found in mitochondria and is encoded by the 
ALDH2 gene. The two genes are 52 kb and 43 kb in length and are present on chromosome 9 
and chromosome 12 respectively. Both genes have a similar structure with 13 exons and the 
protein encoded by both the genes is 70% similar in sequence and structure (Hurley et al., 
2002). ALDH1A1, ALDH1B1 and ALDH2 are mainly involved in acetaldehyde oxidation. 
 
Fig. 1. Metabolism of alcohol in liver hepatocytes using 3 systems, (i) Alcohol 
dehydrogenase, (ii) Microsomal ethanol oxidizing enzyme (iii) Catalase and finally 
Aldehyde dehydrogenase converts acetaldehyde into acetate  
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2.3 Microsomal ethanol oxidizing enzymes 
Apart from ADH which accounts for greater part of ethanol oxidation, a quantitatively small 
portion of alcohol is catalyzed by microsomal ethanol oxidizing system involving CYP2E1 
(Edenberg, 2007). Studies have shown that CYP2E1 is induced by high ethanol concentration 
and by chronic intake of alcohol or ethanol (up to 10 fold) (Quertemont, 2004). It has been 
found that after chronic ethanol consumption CYP2E1 increases the rate of ethanol clearance 
and this may result in development of ethanol tolerance (Lieber et al., 1968; 1988; Takahashi 
et al., 1993; Tsutsumi et al., 1989). CYP2E1 induction may further lead to higher 
concentrations of acetaldehyde leading to injuries in hepatocytes.  
2.4 Catalase 
Catalase oxidizes alcohol to acetaldehyde within the peroxisomes (Oshino et al., 1973). This 
reaction is hydrogen peroxide (H2O2) dependent. Under normal conditions catalase plays a 
minor role in ethanol oxidation. However, the functional activity of catalase is accelerated in 
the presence of reactive oxygen species and H2O2 (Quertemont, 2004). Zimatkin et al. (1997) 
have suggested that catalase may be one of alternative metabolic pathways for ethanol 
oxidation in brain where CYP2E1 and ADH appear to be of minor importance. However, 
the precise role of catalase in brain ethanol oxidation is still not clear.  
2.5 Nonoxidative ethanol metabolism 
Apart from oxidative metabolism of alcohol, nonoxidative metabolism also takes place in 
organs lacking oxidative metabolism such as heart (Beckemeier et al., 1998). A minor extent 
of alcohol is metabolized by nonoxidative pathway using enzyme fatty acid ethyl synthases 
resulting in the formation of fatty acid ethyl esters (Caballeria 2003). Further, these esters 
have been found to be involved in alcohol-induced organ injuries (Beckemeier et al., 1998).  
3. Genetic variants affecting alcohol metabolism 
Genes encoding for alcohol metabolizing enzymes are supposed to have major influence on 
development of alcoholism. There are multiple ADH and ALDH enzymes encoded by 
different genes. Some of these genes have been reported to occur in several variants or 
alleles. The enzymes encoded by different alleles can differ in the rate at which they 
metabolize ethanol (Edenburg, 2007). 
3.1 Genetic variants of alcohol dehydrogenase 
Researchers have studied the genetic variants of ADH1B and ADH1C genes that result in 
the production of enzymes with different kinetic properties and have been implicated in the 
susceptibility to develop alcoholism. These genetic variants or SNPs and their effects have 
been widely studied in different populations and three different alleles have been reported 
which alter the amino acid sequence of the encoded beta subunit. ADH1B*1 allele, (reference 
allele) encodes for ǃ1 subunit that has arginine at positions 48 and 370. ADH1B*1 is the 
predominant allele in most populations. ADH1B*2 encodes for ǃ2 subunit with histidine at 
position 48 and is commonly found in Asians. ADH1B*3 encodes for ǃ3 subunit that has 





amino acid substitutions occur at an amino acid which contacts with coenzyme 
nicotineamide dinucleotide (required for ethanol oxidation) (Hurley et al., 2002). The 
substitution results in enzymes, which have 70- to 80- fold higher turnover rate than the ǃ1 
subunit. This is because the coenzyme is released more rapidly at the end of reaction. 
For ADH1C gene, there are 3 alleles ADH1C*1 encoding Ǆ1 subunit with arginine at position 
272 and isoleucine at position at position 350. ADH1C*2 encodes the Ǆ2 subunit which has 
glutamine (Gln) at position 272 and a valine (Val) at position 350. These two SNPs occur 
together (i.e., are in very high linkage disequilibrium). It has been found that the ADH with 
two Ǆ1 subunits (i.e., the Ǆ1Ǆ1 homodimeric enzyme) has a turnover rate that is about 70 
percent higher than that of the Ǆ2Ǆ2 enzyme (Edenberg, 2007). ADH1C*Thr352 encodes for a 
subunit with threonine at position 352 and has been found in Native Americans (Osier et al., 
2002). However, the studies on this protein are still lacking. Researchers have identified the 
differences in the rate of metabolism of ethanol in liver on the basis of difference in amino acid 
sequence resulting in difference in kinetic properties of encoded enzyme. If a person carries 
two copies of reference allele i.e. ADH1B*1 and ADH1C*1 alleles (homozygous for 
ADH1B*1and ADH1C*1) the enzyme (together ǂ, ǃ, Ǆ subunits) together accounts for liver’s 
70% ethanol oxidizing capacity, additionally π ADH accounts for 30% (Hurley et al., 2002). 
ADH1B*1 allele has been reported to reduce the occurrence of alcohol abuse and alcoholism in 
Asians, in Whites and in Jewish populations where this allele has a relatively high prevalence 
(Carr et al., 2002; Neumark et al., 1998). ADH1B*2 has been found to occur in a higher 
frequency in nonalcoholics and in moderate drinkers relative to heavy drinkers. As far as 
ADH1B*2 is concerned, this allele has been found to be associated with lower rates of heavy 
drinking and alcohol dependence in Native Americans (Quertemont, 2007). 
A meta-analysis conducted by Whitfield has concluded that ADH1B*1 allele is associated 
with a threefold increase in risk of alcoholism in comparison with ADH1B*2 allele.ADH1B*2 
allele encodes for an enzyme with a faster ethanol oxidation rate (Whitfield, 1997). It has 
been assumed that this allele protects against alcoholism and alcohol abuse because of the 
unpleasant effects associated with acetaldehyde accumulation (Yin, 1994). The frequency of 
ADH1C*1 allele has been reported to about 50% in European population and up to 90% in 
some Asian and African populations (Goedde et al., 1992; Osier et al., 2002). This allele has 
also been shown to provide a protection against alcohol abuse and alcoholism since a higher 
frequency of this allele has been found in nonalcoholics especially from Asian population. 
Gene-gene interactions have also been found to play an intricate role in development of 
alcoholism. Oseir et al. (2004) found that there is potential epistatic interaction between 
ADH1B and ADH7 which leads to protective effect against alcoholism among Han Chinese 
population (Oseir et al., 2004). 
3.2 Genetic variants of aldehyde dehydrogenase (ALDH) 
The best known variation of alcohol metabolizing enzymes has been associated with 
ALDH2 gene. A variant of this gene known as ALDH2*2 allele leads to the substitution of 
lysine to glutamine at 504 position (Chou et al., 1999). This substitution results in the 
production of a nearly inactive ALDH2 enzyme which no longer oxidizes acetaldehyde to 
acetate. Studies have demonstrated that this variant is dominant because people who are 
heterozygous (ALDH2*1 and ALDH2*2) have almost no detectable activity of ALDH2 
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enzyme in the liver. People with an ALDH2*2 allele show an alcohol flush reaction even 
when they consume alcohol in relatively small amounts (Harada et al., 1981). The presence 
of even a single ALDH2*2 allele has been shown to be strongly protective against alcohol 
dependence. The protective effect of ALDH2*2 is the most widely reproduced association of 
a specific gene with alcoholism (Chen et al., 1999; Hurley et al., 2002; Luczak et al., 2006; 
Thomasson et al., 1991). 
3.3 Genetic variants of microsomal ethanol oxidizing system 
Another enzyme, microsomal ethanol oxidizing enzyme involved in alcohol metabolism is 
encoded by CYP2E1 gene. CYP2E1 is induced (increase in activity up to 10 fold) by chronic 
alcohol drinking and may contribute to development of metabolic tolerance in alcoholics. 
Studies have revealed that polymorphism in CYP2E1 (CYP2E1*1D) has been found to be 
significantly associated with alcohol dependence in Canadian native Indians (Howard et al., 
2003; Itoga et al., 1999). Another rare mutant named as c2 allele (CYP2E1*5B) in CYP2E1 
gene has been found to be associated with higher transcriptional activity leading to elevated 
level of the enzyme as compared to wild type c1 allele i.e. CYP2E1*5A (Hayashi et al., 1991). 
3.4 Genetic variants of catalase 
Studies have revealed that subjects with positive family history of alcoholism have a higher 
mean activity of catalase as compared to control subjects (Koechling and Amit et al., 1992). 
A significant positive correlation was observed in brain and blood catalase activity in rats 
(Amit and Aragon., 1988). Koechling and Amit (1992) have reported a significant coorelation 
between blood catalase activity with alcohol consumption. However, there are no studies on 
the association of genetic polymorphism of catalase with alcoholism.  
4. Neuropharmacological aspects of chronic alcoholism 
The neuropharmacological actions of alcohol such as cognitive impairment and other 
behavioral changes are mediated via their interaction with brain neurotransmitters. 
Neurotransmitters are the chemicals involved in communication of neurons in brain and 
may be inhibitory or excitatory depending upon their mechanism of action. Although 
alcohol does not have any specific target neurotransmitter, it acts on multiple 
neurotransmitter systems (Deitrich and Erwin, 1996; Tabakoff and Hoffman, 1992). 
Chronic alcohol consumption may cause cognitive impairment, tolerance and physical 
dependence due to changes in neurotransmitter system in brain. The neuropharmacological 
changes caused by chronic alcoholism involve monoamine oxidase, neurotransmitter amino 
acids and calcium ion channels and some other pathways leading to neuroadaptations and 
development of tolerance (Zaleski et al., 2004). The complex mechanism of action involving 
neurochemical changes explains why even moderate doses of alcohol may lead the subject 
to develop psychiatric complications and alcohol dependence. The addictive and alcohol 
seeking behavior can be explained by understanding the neurotransmitter involved in the 
processes (Vengeliene et al., 2006).  





4.1 Alcohol and monoamines 
Ethanol affects the release of the main neurotransmitters present in central nervous system, 
such as dopamine, gamma amino butyric acid (GABA), serotonin, noradrenaline and opioid 
peptides (Kianmaa &Tabakoff, 1983; Tabakoff, 1977, 1983). Alcohol activates the firing of 
dopaminergic neurons in the ventral tegmental area and nucleus accumbens structures 
which together are a part of mesolimbic pathway and play an important role for the 
rewarding effect of ethanol (Diana et al., 1992). Studies have demonstrated that the 
stimulation of dopaminergic neurons may indirectly activate serotonergic pathways. The 
low levels of serotonin have been reported to be a risk factor for development of alcoholism 
(Lovinger, 1991).  
4.2 Alcohol and neurotransmitter amino acids 
Several studies have demonstrated the actions of ethanol on neurotransmitter amino acids 
which consist of glutamate-main excitatory neurotransmitter in the central nervous  
system. It has N-methyl-D-aspartate (NMDA) and amino-3-hydroxy-5-methyl-4-
isoxazoleproprionate (AMPA), and kainate receptors. The NMDA receptors are controlled 
by several regulatory sites. To open the channel of NMDA receptor, presence of glycine is 
required. Glycine is an amino acid which has its own site, acting as a coagonist. Alcohol has 
been reported to act on glycine binding site therefore, inhibiting the function of NMDA 
receptor (Woodword, 1994). The receptor has been found to play an important role in 
learning and memory and in development of alcohol tolerance (Longo et al., 2002). 
Glutamate, a neurotransmitter has been found to play a significant role in the pathogenesis 
of alcohol dependence by mediating excitatory pathways (Sander et al., 2000). Chronic 
alcohol use has been found to be associated with upregulation of NMDA receptors. Alcohol 
shows lower affinity for AMPA and kainate glutamate receptors (Ferreira & Morato, 1997). 
In case of acute ethanol withdrawal, NMDA receptor releases increased amount of 
glutamate which is associated with tremors, anxiety, ataxia, and convulsions. 
Alcohol produces sedative-hypnotic effects mediated via GABA, an inhibitory 
neurotransmitter. There are three types of GABA receptors, GABA A, GABA B, and GABA 
C in brain. GABA A receptors are responsible for the intoxicating effects of alcohol such as 
motor incoordination, anxiolysis and sedation. The neurobehavioral effects of ethanol 
mediated via neurotransmitter GABA are directly dose-dependent. The effects of alcohol at 
GABA A receptors vary across brain regions. This might be due to the differential 
expression of GABA A receptor subunits (Loh et al., 1999). 
Another neurotransmitter, Neuropeptide Y (NPY) is an amino acid peptide which has been 
associated with reward, appetite and anxiety. The association of NPY has also been reported 
with alcohol dependence in animal models. NPY-deficient mice  have been reported to show 
higher alcohol consumption as compared with wild type mice (Thiele et al., 1998). 
4.3 Alcohol and calcium ion channels 
Voltage sensitive calcium channels (VSCCs) play a major role in gating synaptic calcium 
influx and thereby modulating a range of calcium dependent intracellular processes, 
membrane potential, and neurotransmitter release (Kennedy & Liu, 2003). The types of 
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VSCC are of L-type (dihydropyridine-sensitive), N-type (neuronal), P-type (Purkinje), R-
type (Resistant), and T type (transient) channels.  It has been found that alcohol (ethanol) 
blocks L-type channels. The L-type VSCC antagonists show some ethanol, like effects in rats. 
Evidence suggested that chronic administration of alcohol in mice up-regulates the number 
and function of N-type calcium channels. Ethanol actions at VSCCs may modulate its 
behavioral effects in humans (Zaleski et al., 2004). It has been reported that there is an 
increase in the inflow of Calcium ions through these channels, contributing to the 
development of withdrawal symptoms such as seizures and craving. 
4.4 Alcohol and other mechanisms of actions 
Studies assessing cognitive functions have associated the chronic ingestion of ethanol with 
the reduction in concentration of acetylcholine in humans as well as mice, caused by the 
degeneration of brain tissues which seems to be related to the development of tolerance of 
alcohol. Chronic consumption of alcohol may affect opioid receptor system thus exerting 
neurobehavioral effects such as reinforcement. The three major classes of opioid system are 
µ, ǅ and κ. Alcohol may stimulate the release of certain opioid peptides such as endorphins 
and enkephalins, which in turn, could interact with the centers (mesolimbic dopamine 
pathway) of the brain, associated with reward and positive reinforcement and may lead to 
further alcohol consumption (Vengeliene et al., 2008). Human and animal studies have 
suggested that µ opioid receptor is mainly involved in initial sensitivity and response to 
alcohol. The increased activity of brain opioid peptide systems, in response to ethanol 
exposure, may be important for initiating and maintaining high alcohol consumption and 
for mediating the positive reinforcing effects of alcohol (Gianoulakis et al., 1996). 
5. Genetic variants of neurotransmitters 
Alcohol exerts its effects such as reward and reinforcement by acting on a number of 
neurotransmitter in the brain. Studies have revealed that polymorphisms in genes encoding 
for neurotransmitter may increase the risk of developing alcoholism (Radel & Goldman, 
2001; Foley et al., 2006). The knowledge of gene variants affecting neurotransmitters is very 
important as it serves the basis for developing novel and targeted therapeutic agents in 
treatment of alcoholism. A few of the genetic variants of neurotransmitters associated with 
alcohol dependence are as:  
5.1 Glutamate 
Candidate gene studies have shown that individuals bearing G603A polymorphism of glial 
glutamate transporter gene (EAAT2) are at increased risk of alcoholism (Sander et al., 2000). 
The individuals with genetic variants of NMDA (subunit NR2A) and glutamate receptor 
metabotropic gene (mGLUR5) have been studied in a hospital based study in Germany 
(Schumann et al., 2008). It was found that carriers of the NR2A risk genotypes for rs2072450 
CC and rs9924016 Del/Del had higher risk of developing alcohol dependence  as compared to 
the individuals with protective genotypes rs2072450 AC and rs9924016 Del/Ins (Schuman et 
al., 2008). In the case of mGLUR5 gene, individuals of the risk genotypes rs3824927 C/C and rs 
3462 G/G have been  found to be at higher risk of developing alcohol dependence when 





5.2 Gamma amino butyric acid 
Association of genetic variants of GABARA1 and GABAR6 with alcoholism has been reported 
in Korean population (Park et al., 2006).The GG genotype of GABAA1 receptor has been found 
to be significantly associated with early onset and severity of alcoholism in Korean population 
(Park et al., 2006). It has been also been reported that Pro385Ser substitution in GABA A6 is 
associated with alcohol dependence and with antisocial alcoholism (Sander et al., 1999).  
5.3 Norepinephrine 
Studies have suggested that alcohol produces biphasic effects on norepinephrine turnover in 
the brain, with low doses increasing turnover and higher doses depressing turnover. The 
sensitivity of noradrenergic systems to ethanol effects varies among brain regions. A few 
studies have been attempted to see the effect of genetic variants of norepinephrine on 
alcoholism. Huang et al. (2008) reported that norepinephrine transporter polymorphisms T-
182C and G1287A are not associated with alcohol dependence and its clinical subgroups in 
Han Chinese population. 
5.4 Dopamine 
Research studies have revealed that there is a positive association between polymorphism in 
Dopamine receptor gene (DRD) with alcoholism. Ponce et al. (2008) reported that the two 
SNPs (-141C Ins/Del) and TaqI A, present on DRD2 gene locus were associated with 
alcoholism in North Indian population. Studies from South Indian population have reported 
no association between TaqI A polymorphism and alcoholism. 
The -141 Ins/Del polymorphism in DRD2 gene has been found to be associated with 
alcoholism in several studies across different populations, but with inconsistent results. This 
promoter polymorphism plays a significant role in D2 receptor expression via altering the 
transcriptional activity. Johann et al. (2005) studied the association of -141I Del variant (-
141C) SNP in German alcoholics. It was found that -141 Del C variant of DRD2 gene might 
be a protective factor against development of alcoholism. On the other hand the -141 Ins 
allele has been found to be a genetic risk factor for alcoholism in Mexican-Americans. This 
can be correlated with decreased DRD2 receptor density in alcoholic patients which in turn 
stimulates craving-reward pathway- thereby promoting alcoholism. 
Another polymorphism in DRD2 gene Taq I A in Ankyrin repeat and Kinase Domain 
containing (ANKK1)( rs 1800497) is one of the most frequently studied mutations. The 
DRD2 gene is actually not located on DRD2 but rather within the protein coding region 
exon 8 of the adjacent ANKK1gene (Neville et al., 2004). TaqI A SNP causes an amino acid 
substitution within the 11th ankyrin repeat of the putative protein and has been found to 
affect the substrate binding specificity (Ponce et al., 2008). In a meta-analysis, the single 
nucleotide variant TaqIA (rs 1800497) of the DRD2 gene has been found as a vulnerability 
gene for alcoholism in more than 40 studies, but with conflicting results. 
5.5 Serotonin  
The genetic variants of serotonin receptor gene for example rs1042173  may influence 
alcohol dependence (Jhonsan et al., 2011). The presence of genetic variation may lead to 
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manipulation of serotonergic transmission therefore affecting the rate of development of 
tolerance and alcohol dependence (Yoshimoto et al., 1996).  
5.6 Cholinergic and nicotinic receptor gene  
Evidence from genetic studies suggested that alcohol dependence as well as cigarette 
smoking in families share the genetic vulnerability. Research studies have identified a 
missense mutation (rs16969968) in exon 5 of the nicotinic receptor (CHRNA5) gene and a 
variant in the 3′-UTR of the CHRNA3 gene in association with alcoholism and nicotine 
dependence (Wang et al., 2009). Cholinergic muscarinic 2 receptor (CHRM2) SNP 
(rs1824024) has been significantly associated with the pathogenesis of depression and 
alcohol dependence disorders (Jung et al., 2011; Luo et al., 2005). 
5.7 Opioids 
Bart et al. (2005) have identified positive association between A118G polymorphism and 
increased risk of alcohol dependence in individuals from Sweden. The single nucleotide 
polymorphism A118G in exon 1 of opioid receptor gene (OPRM1) results in increase in 3 
fold binding capacity of beta endorphin. However, the results of a number of research 
studies are contradictory. Few studies have failed to find the association between the A118 
G allele and alcoholism (Bergen et al., 1997; Franke et al., 2001; Gelernter et al., 1999; Kim et 
al., 2004; Kranzler et al., 1998;  Schinka et al., 2002), while  few others have found positive 
association between the A118 allele and alcoholism (Town et al., 1999). The explanations for 
these conflicting reports may be small sample size of the populations under study and the 
ethnic variation. 
5.8 Other neurotransmitters (Neuropeptide Y) 
In Humans, Leu7Pro polymorphism in NPY gene has been established to affect the release 
of mature NPY. Individuals with Pro7/Leu7 allele have 42% higher plasma concentration of 
NPY as compared with Leu7/Leu7 variant. Kauhanen et al. (2000) reported that Pro7allele is 
associated with more (34% higher) alcohol consumption in a cohort of Finnish middle aged 
men.  Lappalainnen and others have reported that NPYPro7 allele significantly contributes 
towards the heritability of alcohol dependence in European American population 
(Lappalainnen et al., 2002). 
6. Pharmacotherapy of alcoholism 
The first step in the treatment of alcoholism is detoxification assisted by medical 
treatment (Wertheimer and Chaney 2003). Detoxification is required to manage the 
clinical and psychological symptoms of alcoholism. After detoxification there is need for 
counseling or psychotherapy and rehabilitation (Williams, 2001). The pharmacological 
agents or medicines in use for alcoholism treatment act on specific neurotransmitter 
systems. The treatment is aimed at normalizing the alcohol specific neuroadaptations 
(Krishnan-Sarin et al., 2008). The selection criteria for treatment of alcoholism is based on 






6.1 FDA approved drugs for treatment of alcoholism 
Some of the drugs approved by FDA for treatment of alcoholism are as follows (Krishnan- 
Sarin et al., 2008). 
6.1.1 Disulfiram 
Disulfiram has been in use to treat alcoholism since 1940. Disulfiram produces an aversive 
effect by disrupting alcohol metabolism. The proposed mechanism of action of disulfiram on 
alcohol use has been found to be primarily related to the inhibition of liver aldehyde 
dehydrogenase (metabolizing enzyme of alcohol) and secondarily related to central nervous 
system actions, via modulation of catecholamine neurotransmission. It blocks ALDH 
activity by forming intermolecular disulfide bridges resulting in acetaldehyde accumulation. 
Excessive buildup of acetaldehyde results in many unpleasant effects including lowered 
blood pressure, palpitation, nausea, vomiting, headache and difficulty in breathing.  
In clinical doses, disulfiram inhibits the enzyme dopamine–ǃ–hydroxylase, which converts 
dopamine to norepinephrine, leading to increase in dopamine levels in brain (Goldstein & 
Nakajima, 1967; Goldstein et al., 1964). It has been found in clinical trials of disulfiram that 
there are lower rates of relapse to drinking in those who are compliant with the medication 
(Fuller et al., 1986). However, due to aversive nature of this drug, noncompliance is one of 
the biggest problems encountered with its use. The use of disulfiram is supervised in many 
clinical settings.  
6.1.2 Naltrexone 
Naltrexone is a drug used mainly for the treatment of alcohol dependence, and is available 
as oral medication and in injectable form. The drug is well tolerated with primary 
gastrointestinal side effects (O’Malley et al., 1992; Volpicelli et al., 1992). The efficacy of 
naltrexone in reducing alcohol drinking is mediated via interactions between the 
endogenous opioid system and dopamine systems, specifically through antagonism of the 
μ−opioid receptors. The studies on animal models suggested that alcohol increases release 
of ǃ−endorphins in certain portions of the brain known to be involved in alcohol reward 
(Marinelli et al., 2003; Zalewska-Kaszubska et al., 2006). Nalotrexane blocks the release of 
these endorphins. Naltrexone has also been shown to reduce drinking in animal models 
(Froehlich et al. 2003; Swift, 2000).  
A number of clinical trials indicate that alcoholics receiving naltrexone treatment in 
combination with behavioral intervention have lower levels of relapse and reduced levels of 
alcohol craving (O’Malley et al., 1992). Recent reports (Bouza et al., 2004; Srisurapanont & 
Jarusuraisin, 2002) suggest that naltrexone has modest efficacy in preventing relapse to 
drinking. Although, naltrexone is well tolerated, the potential risk of toxicity of liver at high 
doses is the major cause of concern in patients with liver disease.  
6.1.3 Acamprosate 
Acamprosate is available in an oral, delayed release formula, Camprel. The mechanism of 
action is through antagonizing of the N-methyl D-aspartate (NMDA) glutamate receptor site 
or via modulation of glutamate neurotransmission (DeWitte et al., 2005; Harris et al., 2002). 
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It has been found that acamprosate reduces neuronal hyperexcitability during alcohol 
withdrawal, due to reductions in glutamate levels, so as to normalize the balance between 
excitatory and inhibitory neurotransmitters produced in chronic alcohol consumption 
(Spanagel et al., 1996; Dahchour et al., 1998; Littleton & Zieglgansberger, 2003).  
6.2 Other promising medicines 
In addition to the drugs approved by FDA for treating alcoholism there are other 
medications which are in use because of some clinical evidence of efficacy. 
6.2.1 Ondansetron 
Ondansetron is a 5HT3 receptor antagonist used mainly as antinausea medicine after 
postoperative nausea and as anticraving medicine in alcoholism. Human laboratory studies 
have demonstrated that ondansetron decreases alcohol preference and desire to drink 
(Johnson et al., 1993). The efficacy of ondansetron in reducing drinking behavior has also 
been reported in Clinical trials, especially in drinkers with early onset alcoholism (Kranzler 
et al., 2003). 
6.2.2 Baclofen 
Baclofen, a GABA B receptor antagonist is used clinically for the treatment of muscle 
spasticity. The preclinical trials have shown the effectiveness of baclofen in reducing chronic 
alcoholism (Colombo et al., 2004). In a recent clinical trial, it was found that the drug is well 
tolerated in alcohol dependent patients with liver cirrhosis and has some efficacy in 
improving abstinence rates. However, more clinical research is needed to establish its 
efficacy and tolerability in alcoholic patients. 
6.2.3 Topiramate 
Topiramate is an antiseizure medication which has been shown to be effective in reducing 
alcohol use in recent clinical trials. Its action is mediated via antagonizing ǂ amino-3-
hydroxy 5-methylisoxazole 4-propionic acid (AMPA) and kainate glutamate receptors as 
well as inhibition of GABA A receptors, L type calcium channels, and voltage dependent 
sodium channels (SCN). Topiramate has been shown to reduce alcohol use in animal models 
(Farook et al., 2007). It also helps in reducing alcohol withdrawl induced convulsions. It has 
some side effects such as numbness, anorexia, cognitive difficulty, and taste distortion, as 
well as some rare incidents of visual side effects including myopia, glaucoma, and increased 
intraocular pressure. The clinical trials used a slow titration over several weeks to the 
desired dose to reduce the incidence of side effects. 
6.2.4 Selective serotonin reuptake inhibitors (SSRI) 
Selective serotonin reuptake inhibitors such as fluoxetine, citalopram, and sertraline are 
used in the treatment of alcoholism because existing evidence has shown that lowering 
brain serotonin levels decrease preference for alcohol and SSRI.  SSRI’s are basically used in 
the treatment of depression, therefore the effectiveness has been found in depressed 





7. Pharmacogenetics of alcoholism 
The sequencing of the human genome has become the foundation for one of the most 
significant scientific contribution, the idea that although all human individuals are 
genetically similar, each retains a unique genetic identity. The publication of the human 
blueprint has triggered an explosion in pharmaceutical research to utilize this knowledge in 
the prescription of drugs for various ailments including alcoholism to be tailored according 
to the genetic makeup of susceptible individuals or in other words personalized medicine. 
Just before half a century ago the Human Genome Project, scientists had realized that 
inheritance was an important factor which accounts for individual variation in drug 
response (Kalow, 1962; Venter et al., 2001). This led to the birth of the term 
Pharmacogenetics. Pharmacogenetics is the study of the role of inter-individual genetic 
variation in drug response. Although human beings are 99.9% similar in their genetic 
makeup, 0.1% variability in terms of single-nucleotide polymorphisms is significantly 
accountable for an individual’s susceptibility to diseases and inter- and intra-individual 
variation of drug response (Brooks, 1999). 
On the basis of our current understanding of neurobiology numerous candidate genes have 
been implicated in the etiology and response to treatments for different addictions including 
alcoholism. The focus is on functional genetic variants of proteins involved in the neural 
response to alcohol including alcohol sensitivity, reward and tolerance and variants of the 
enzyme involved in metabolism of alcohol. 
8. Genetic predictors of medication response  
The inter-individual variation in drug response results in categorization of alcoholic patients 
into responders and nonresponders. The responders experience therapeutic efficacy with a 
particular drug given in therapeutic range without any toxicity or adverse effects. The 
nonresponders do not show any therapeutic effect, even when the administered drug 
reaches to peak level in blood, leading to ineffective treatment, known as poor as poor 
metabolizers. Therefore the traditional approach of one dose fits for all is no longer helpful 
in predicting the therapeutic efficacy of a drug. The pharmacogenetics focuses on 
identifying genetic factors that is with are responsible responsible for variability in 
pharmacotherapeutic effect both in terms of pharmacodynamics and efficacy (Evans 
&Johnson, 2001). The field has greatly benefitted from advances in molecular genetic tools, 
developments in bioinformatics and functional genomics for identifying genetic variants. 
Genetic factors can account for interindividual differences in drug toxicity and efficacy in 
many ways e.g. the variability in genes may lead to differences in drug metabolism and 
disposition through functional differences in activity of enzymes or drug transporters (Ray 
et al., 2010a). Alternatively genetic variation may impact a drug’s target such as particular 
receptor. Genetic variants that may modulate the effects of naltrexane have been identified 
in the gene coding for µ OPRM1, which is the primary target of naltrexaone (Oslin et al., 
2003). One of the most widely studied SNPs in OPRM1 is +118A/G (rs 1799971) located in 
the +118 position of exon1 one which encodes for Asn40Asp substitution (Bond et al., 1998). 
This A/G substitution has been reported to affect the receptor affinity for endogenous 
ligands, ǃ-endorphin leading to gain in function such that the G variant was thought to bind 
ǃ-endorphin with greater affinity than A allele. However, some recent studies have shown 
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that G allele has a loss of function rather than a gain. Further, the results of the study testing 
the relationship between this SNP of the OPRM1 gene and alcoholism have shown 
inconsistent results, some support the association of this SNP and alcohol dependence while 
others have failed to replicate this association (Schinka et al., 2002; Kranzler et al., 1998; Town 
et al., 1999). Further, this SNP of OPRM1 gene has also been associated with a differential 
response in clinical trials of naltrexone. Oslin et al. (2003) has reported that this SNP is 
associated with clinical response to naltrexaone among alcohol dependent patients such that 
individuals with at least one copy of the G allele, coding for more potent OPRM1 receptor 
reported lower relapse rates and longer time to return to heavy drinking after treatment with 
naltrexone, in comparison with individuals who were homozygous for the A allele. 
It has been reported that persons of Asian descent possess an ALDH2*2 genetic variant 
(Quertemont et al., 2004). ALDH2*2 genetic variant of the ALDH enzyme metabolizes 
slowly and leads to accumulation of acetaldehyde (Edenberg, 2007). When the individuals 
bearing this variant drink alcohol they develop high acetaldehyde blood concentration and 
experience of flushing reaction similar to that seen in combination of ethanol and disulfiram. 
ALDH2*2 variation is the best characterized genetic factor protecting against the 
development of alcohol dependence. Pharmacogenomic studies suggest that it is highly 
unlikely that disulfiram will be helpful in treating the patients who have genetically 
compromised ALDH. 
In addition disulfiram chelates copper and thus inhibits copper containing enzyme 
dopamine beta hydroxylase which further inhibits norepinephrine and dopamine in brain 
(Haile et al., 2009). The individuals harboring TT allele of dopamine beta hydroxylase (DǃH) 
gene with C1021T polymorphism respond better to disulfiram treatment and need less dose 
whereas carriers (CT) would need intermediate dose and those with CC allele need 
maximum concentration to reach the efficacy level. 
Acamprosate, is a drug used for abstinence and maintenance as it reduces craving in 
alcoholic patients who have undergone detoxification (De Witte et al., 2005). The effective 
acamprosate response in alcohol dependent subjects may be influenced by genetically 
controlled variation of NMDA receptor and the type of glutaminergic mGLU5 receptor. 
Confirmation of this hypothesis could lead to development of effective individualized 
treatment and recommendation for alcohol dependent patients based on 
pharmacogenetically relevant genetic variant. 
Ondansetron, an antagonist of serotonin is important in the treatment of alcoholism. 
Serotonin transporter gene is an important regulator of neuronal 5-HT’s function. The 
genetic difference in this gene may modulate the severity of alcohol consumption and 
predict the therapeutic response to 5-HT3 receptor antagonist ondansetron. A variable 
tandem repeat polymorphism (5-HTT LPR) is common in the promoter region of 5-HTT 
gene which alters the transcriptional activity. Two important variants are long (insertion LL) 
and short (SS) version. It has been reported in a randomized clinical trial that individuals 
with LL genotype (Homozygous for the long version) of 5-HTT gene showed significant 
results in improvements of alcoholism with treatment of ondansetron as compared to LS 
and SS genotype (Johnson et al., 2011). 
Another functional T/G polymorphism (rs1042173) as in the 3/ untranslated region of the 5-





alcohol addiction treatment (Jhonsan et al., 2011).  The effect of ondensateron will be higher 
in individuals possessing the combination of LL genotype and TT genotype of 5-HTT gene.  
 
Fig. 2. Alcoholism Treatment: A Treatment approach to use a trio of Pharmacotherapy using 
pharmacological agents, where a traditional approach of “One dose for all” is used and 
Psychotherapy – an important part of treatment in alcoholism and Pharmacogenetics based 
on Genetic makeup of the Individual for better and effective treatment in alcoholism 
9. Conclusion 
Lot of work still needs work still needs to be done in order to improve our understanding of 
the genetic and environmental factors underlying alcohol dependence and also utilizing the 
genetic information in prescribing the drugs as per the genetic architecture of the 
individuals. The integrated approach of incorporating a trio of pharmacogenetic, 
pharmacotherapy and psychotherapy would be more promising in treatment of alcoholism 
(Fig 2). As the genetic testing becomes more common in the practice of medicine variety of 
ethical and practical challenges unique to alcohol addiction, will also need to be addressed. 
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